ReviewPharmacology & therapeutics2013
Tumor stroma as targets for cancer therapy.
Review in Pharmacology & therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed.
- Conformation-Specific Design: Engineering Extracellular Signal-Regulated Kinase 2 Variants with Bias toward Active or Inactive States.ACS omega · 2026Article
- Estrogen receptor positivity in stromal cells of the tumor bed predicts the response to neoadjuvant chemotherapy for breast carcinoma.Breast cancer research and treatment · 2025Article
- A multi-omics atlas of CAF subtypes reveals apCAF-M2 macrophage interactions driving immune resistance in glioma.PloS one · 2025Article
- Article
- The tumor-stroma ratio in giant cell tumor of bone: associations with the immune microenvironment and responsiveness to denosumab treatment.Journal of orthopaedic surgery and research · 2024Article
- The Metformin Immunoregulatory Actions in Tumor Suppression and Normal Tissues Protection.Current medicinal chemistry · 2024Review
- Prognostic model development for classification of colorectal adenocarcinoma by using machine learning model based on feature selection technique boruta.Scientific reports · 2023Article
- Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- 3D Multicellular Tumor Spheroids in a Microfluidic Droplet System for Investigation of Drug Resistance.Polymers · 2022Article
- Modelling liver cancer microenvironment using a novel 3D culture system.Scientific reports · 2022Article
- Desmoplastic Reaction, Immune Cell Response, and Prognosis in Colorectal Cancer.Frontiers in immunology · 2022Article
- The interactions between integrin αInternational journal of biological sciences · 2022Article
- Development of a Platelet-Related Prognostic Model for Colorectal Cancer.Frontiers in genetics · 2022Article
- NF-κB and Pancreatic Cancer; Chapter and Verse.Cancers · 2021Review
- Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.International journal of molecular sciences · 2021Review
- Recent Progress in the Design and Medical Application of In Situ Self-Assembled Polypeptide Materials.Pharmaceutics · 2021Review
- Proteomics reveals the function reverse of MPSSS-treated prostate cancer-associated fibroblasts to suppress PC-3 cell viability via the FoxO pathway.Cancer medicine · 2021Article
- Review
- Advances in research on the interaction between inflammation and cancer.The Journal of international medical research · 2020Review
- Association of the tumour stroma percentage in the preoperative biopsies with lymph node metastasis in colorectal cancer.British journal of cancer · 2020Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cancer is not only composed malignant epithelial component but also stromal components such as fibroblasts, endothelial cells, and inflammatory cells, by which an appropriate tumor microenvironment (TME) is formed to promote tumorigenesis, progression, and metastasis. As the most abundant component in the TME, cancer-associated fibroblasts (CAFs) are involved in multifaceted mechanistic details including remodeling the extracellular matrix, suppressing immune responses, and secreting growth factors and cytokines that mediate signaling pathways to extensively affect tumor cell growth and invasiveness, differentiation, angiogenesis, and chronic inflammatory milieu. Today, more and more therapeutic strategies are purposefully designed to target the TME as well as tumor cells. This review will focus on the role of CAFs in tumor development and the novel strategies to target this component to inhibit the tumor growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.